Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab.

Autor: Velez C; Department of Pediatric Nephrology, Pablo Tobón Uribe Hospital, Medellín, Colombia., Zuluaga G, Ocampo C, Aristizabal A, Serna LM, Serrano Gayubo AK, Florez JA, Zuleta JJ, Vanegas Ruiz JJ
Jazyk: angličtina
Zdroj: Transplantation proceedings [Transplant Proc] 2011 Nov; Vol. 43 (9), pp. 3350-4.
DOI: 10.1016/j.transproceed.2011.09.101
Abstrakt: Background: Renal transplantation is the most effective treatment for children with end-stage renal disease. Recent work suggests that induction with alemtuzumab in the pediatric population permits the use of lower doses of maintenance immunosuppressive therapy. In addition, it has a low cost compared with other induction therapies.
Objective: To conduct a clinical description of pediatric renal transplant patients comparing induction protocols to evaluate graft and patient survival, infections complications, and lymphoproliferative diseases.
Materials and Methods: This descriptive and retrospective study, of evaluated pediatric renal transplant patients between 2006 and 2010.
Results: The agents for induction therapy were: alemtuzumab (61.5%), daclizumab (19.25%), and thymoglobulin (19.25%). Graft survival was better among the alemtuzumab group (87.5%) compared with the other two induction therapies (80%). The frequency of acute rejection episodes during the first year posttransplantation as well as chronic rejection was lower among the alemtuzumab group. Cytomegalovirus infection was noted in 30% of patients with greater frequency among those induced with alemtuzumab.
Conclusion: Induction therapy with alemtuzumab was safe in a pediatric population not predisposing to a greater risk of acute or chronic rejection. Except for a greater incidence of Cytomegalovirus, there was no difference in other complications.
(Copyright © 2011. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: